An exploratory post hoc analysis of SURPASS-4 showed that tirzepatide reduced the decline in eGFR and decreased the urine albumin-to-creatinine ratio (UACR) compared with insulin glargine in individuals with T2DM and high cardiovascular risk. Here, INS is linked to type 2 diabetes mellitus.